TQB-2618

N/A

Report date: 2024/12/17 14:20:59

Base Information

Drug NameTQB-2618
Drug Alias NameTQB-2618
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsHepatitis A virus cellular receptor 2 inhibitorsT lymphocytes stimulants
TargetsHepatitis A virus cellular receptor 2
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesColorectal Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyelodysplastic SyndromesNasopharyngeal Carcinoma +[7] 
Inactive IndicationsColorectal NeoplasmsEsophageal Squamous Cell CarcinomaCarcinoma, Hepatocellular +[4] 

Other Information

ATC CodeN/A
Related LinksN/A